The overall objective was to explore if FGF21 could be used safely and efficaciously to treat common obesity-associated metabolic dyscrasias, utilizing a research colony of obese and overweight cats with similar insulin resistance and metabolic alterations. Here, FGF21 is linked to Insulin resistance.